Ep. 252, Chapter 1: Tolga Tanguler & Alnylam

00:00 – 10:49

Chief Editor of Life Science Leader and Host of The Business of Biotech, Ben Comer, and Tolga Tanguler, EVP and CCO and at Alnylam Pharmaceuticals, discuss Tanguler’s career path from Merck and Pfizer to Alnylam Pharmaceuticals, an innovator in the RNA interference (RNAi) therapeutic space. Tanguler details how early work in a stigmatic disease area, followed by his son’s childhood leukemia diagnosis, shaped his approach to science and medicine.